Proto360 Health Integrates Phenomix Sciences' MyPhenome® Genetic Test Into Employer Obesity Care Programs

Launching in conjunction with ObesityWeek^® 2026, the partnership allows employers to pair GLP-1 coverage with genetic testing and ongoing physician oversight, bringing more accountability to one of the fastest-rising costs in employee benefits.

• Proto360 Health has partnered with Phenomix Sciences to integrate the MyPhenome^® genetic obesity test into its comprehensive metabolic care program.
• MyPhenome is now part of the diagnostic assessment employees complete before a GLP-1 prescribing decision is made, giving benefits leaders a more accountable way to manage GLP-1 coverage.
• Developed based on research from Mayo Clinic physician scientist Andres Acosta, MD, PhD, MyPhenome is a simple cheek swab test that analyzes a patient's genetics to help clinicians understand the biological factors that may be contributing to their obesity.

ANNAPOLIS, Md., Nov. 12, 2026 /PRNewswire/ -- Proto360 Health, LLC, a metabolic care platform founded by board-certified obesity medicine physicians, today announced a partnership with Phenomix Sciences, the first commercial precision obesity medicine biotechnology company, to integrate the MyPhenome^® genetic obesity test into Proto360's comprehensive metabolic care program. The genetic obesity test is now part of the diagnostic assessment every Proto360 patient completes before treatment begins, including those enrolled in Proto360 through their employer benefits program. 

GLP-1 medications have become one of the largest costs in employer health benefits. The medications now account for 11.4% of annual claims, up from 6.9% in 2023, and can raise employer health plan premiums by nearly 14% annually. Many employees also don't stay on treatment long enough to benefit. Nearly two-thirds of patients who suffer from being overweight or with obesity, and don't have type 2 diabetes, stop GLP-1 treatment within a year. In response, 40% of firms now require employees to work with a dietitian, case manager, or therapist, or join a lifestyle program. Those requirements add support around the medication, but they don't change how the prescribing decision is made.

With MyPhenome, Proto360 brings precision medicine into the initial treatment assessment. Physicians consider each employee's genetic profile alongside metabolic lab work and body composition data before making prescribing decisions. As care continues, the team tracks progress through body composition scales, continuous glucose monitors, wearables, and periodic labs. The approach combines individualized treatment planning with ongoing physician oversight, medication management, and lifestyle support in a single care program, giving employers a more structured approach to managing GLP-1 benefits.

"A physician wouldn't start someone on blood pressure or diabetes medication without a full diagnostic picture and regular follow-up, and obesity care should be held to the same standard," said John Mulligan, MD, founding partner of Proto360. "When employers pair GLP-1 coverage with diagnostic testing and ongoing clinical oversight, they give employees a benefit they can actually measure, instead of open-ended drug spending."

Developed based on research from Mayo Clinic physician scientist Andres Acosta, MD, PhD, MyPhenome is a simple cheek swab test that analyzes a patient's genetic profile to identify the underlying biological factors that can contribute to obesity. Clinicians receive a report that helps inform individualized treatment plans, so care is based on each patient's unique biology.

"Too often, GLP-1 treatment turns into trial and error, and patients are left managing side effects on their own or wondering why a medication isn't delivering the results they expected," said Katrina Mattingly, MD, founding partner of Proto360. "Adding MyPhenome to our initial assessment gives our care team a better understanding of each patient's biology from the first visit."

"Employers need a clearer understanding of what drives treatment response if they want to manage GLP-1 spending effectively, and we believe biology is central to that equation," said Mark Bagnall, CEO of Phenomix Sciences. "Through Proto360, MyPhenome results become part of a care program that helps clinicians make more informed treatment decisions and guide patients beyond the initial prescription."

Proto360 works with employers to pair GLP-1 coverage with genetic screening, clinical guardrails, continued monitoring, and more predictable costs, so benefits leaders can manage metabolic health as an accountable benefit. Its dedicated care team of physicians, physician assistants, and lifestyle coaches handles evaluations, prescribing, and ongoing treatment virtually, so employers can offer specialized obesity care without hiring specialists or building a program themselves. Proto360 also partners with medical practices across primary care and specialty medicine as a white-labeled extension of their care.

The partnership was announced ahead of ObesityWeek^® 2026, where both companies will be in attendance Nov. 14-17 in National Harbor, Md.

For more information, visit proto360health.com.

About Proto360 Health
Proto360 Health, LLC is a physician-developed metabolic care platform and management services organization that helps medical practices and employers deliver consistent care for obesity and metabolic disease through every phase of treatment. Proto360 combines a physician-developed clinical protocol, employed ProtoMD care teams, diagnostic and metabolic monitoring, and nutrition and lifestyle support. Proto360 operates as a white-labeled extension of the referring practice so patients stay connected to their own physicians. Learn more at proto360health.com

About Phenomix Sciences
Phenomix Sciences is a precision obesity biotechnology company transforming obesity care by putting patients at the center of therapeutic innovation. Through proprietary genetic testing, advanced analytics, rich clinical data, and technology exclusively licensed from Mayo Clinic, Phenomix delivers individualized insights into how patients respond to specific weight loss interventions. These insights not only inform clinical decision-making for patients but also help pharmaceutical and medical device partners refine trials, identify high-responder populations, and accelerate the development of more targeted, effective therapies. By aligning patient biology with drug discovery, Phenomix is shaping a more personalized and impactful future for obesity treatment. Phenomix is backed by Health2047, the innovation arm of the American Medical Association, which helps startups transform bold ideas into solutions that change healthcare for the better. Learn more at www.phenomixsciences.com.

SOURCE Proto360 Health